Antibody-directed phototherapy (ADP)

Antibodies

Volumn 2, Issue 2, 2013, Pages 270-305

  Pye, Hayley ^a,c   Stamati, Ioanna ^a   Yahioglu, Gokhan ^a,b   Butt, M Adil ^c   Deonarain, Mahendra ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b PhotoBiotics Ltd   (United Kingdom)

^c National Medical Laser Centre   (United Kingdom)

Author keywords

Antibody targeted; Photodynamic; Photosensitiser drug; Phototherapy; Therapy

Indexed keywords

2 [1 HEXYLOXYETHYL] 2 DEVINYL PYROPHEOPHORBIDE ALPHA; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; AMPHINEX; ANTINEOPLASTIC AGENT; BREMACHLORIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CYCLIN DEPENDENT KINASE; DISULFONATED TETRAPHENYL CHLORIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN; HEMATOPORPHYRIN DERIVATIVE; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; ISOTHIOCYANIC ACID; LASERPHYRIN PLUS APTOCINE; LU TEX; LUTETIUM TEXAPHYRIN; MITOGEN ACTIVATED PROTEIN KINASE; PADOPORFIN; PHOTOCHLOR; PHOTOFRIN; PHOTOSENSE; PHTHALOCYANINE ALUMINUM; POLYVINYL ALCOHOL; PROTEIN TYROSINE KINASE; RADACHLORIN; REACTIVE OXYGEN METABOLITE; TALAPORFIN; TEMOPORFIN; TETRASULFOPHTHALOCYANINE ALUMINUM; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN;

ANTIBODY DIRECTED PHOTOTHERAPY; ANTIGEN BINDING; APOPTOSIS; AUTOPHAGY; CELL DEATH; CONJUGATION; COST EFFECTIVENESS ANALYSIS; GENETIC ENGINEERING; HUMAN; IMMUNOREACTIVITY; NECROSIS; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 84923379737     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib2020270     Document Type: Review

References (174)

1. Deonarain, M. P. Recombinant antibodies for cancer therapy. Expert Opin. Biol. Ther. 2008, 8, 1123-1141.
2. Carter, P. J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 2006, 6, 343-357.
3. Business Insights, L. The Cancer Market Outlook to 2016. Business Insights Ltd (Product Code: BI00042-009): London, UK, 2011.
4. Aggarwal, S. What's fueling the biotech engine-2008. Nat. Biotechnol. 2009, 27, 987-993.
5. Scott, A. M.; Wolchok, J. D.; Old, L. J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12, 278-287.
6. U. S. Food and Drug Administration Home Page. Available online: http://www. fda. gov/default. htm (accessed on 12 April 2013).
7. The Antibody Society Home Page. Available online: http://www. antibodysociety. org/(accessed on 12 April 2013).
8. ClinicalTrials. gov Home Page. Available online: http://www. clinicaltrials. gov/(accessed on 12 April 2013).
9. Nahta, R.; Yu, D.; Hung, M.-C.; Hortobagyi, G. N.; Esteva, F. J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 2006, 3, 269-280.
10. Alley, S. C.; Okeley, N. M.; Senter, P. D. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr. Opin. Chem. Biol. 2010, 14, 529-537.
11. Hughes, B. Antibody-drug conjugates for cancer: Poised to deliver? Nat. Rev. Drug Discov. 2010, 9, 665-667.
12. Adair, J. R.; Howard, P. W.; Hartley, J. A.; Williams, D. G.; Chester, K. A. Antibody-drug conjugates-A perfect synergy. Expert Opin. Biol. Ther. 2012, 12, 1191-1206.
13. Brown, S. B.; Brown, E. A.; Walker, I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004, 5, 497-508.
14. Dolmans, D. E. J. G. J.; Fukumura, D.; Jain, R. K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380-387.
15. Brown, S. B.; Mellish, K. J. Verteporfin: A milestone in opthalmology and photodynamic therapy. Expert Opin. Pharmacother. 2001, 2, 351-361.
16. Babilas, P.; Schreml, S.; Landthaler, M.; Szeimies, R.-M. Photodynamic therapy in dermatology: State-of-the-art. Photodermatol. Photoimmunol. Photomed. 2010, 26, 118-132.
17. Celli, J. P.; Spring, B. Q.; Rizvi, I.; Evans, C. L.; Samkoe, K. S.; Verma, S.; Pogue, B. W.; Hasan, T. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem. Rev. 2010, 110, 2795-2838.
18. Bonnett, R. Chemical Aspects of Photodynamic Therapy; Gordon and Breach Science Publishers: Amsterdam, The Netherlands, 2000.
19. Agostinis, P.; Berg, K.; Cengel, K. A.; Foster, T. H.; Girotti, A. W.; Gollnick, S. O.; Hahn, S. M.; Hamblin, M. R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic therapy of cancer: An update. CA Cancer J. Clin. 2011, 61, 250-281.
20. Lou, P.-J.; Jones, L.; Hopper, C. Clinical outcomes of photodynamic therapy for head-and-neck cancer. Technol. Cancer Res. Treat. 2003, 2, 311-317.
21. Hopper, C.; Niziol, C.; Sidhu, M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. Oral Oncol. 2004, 40, 372-382.
22. Nyst, H. J.; Tan, I. B.; Stewart, F. A.; Balm, A. J. M. Is photodynamic therapy a good alternative to surgery and radiotherapy in the treatment of head and neck cancer? Photodiagnosis Photodyn. Ther. 2009, 6, 3-11.
23. Allison, R. R.; Sibata, C. H. Oncologic photodynamic therapy photosensitizers: A clinical review. Photodiagnosis Photodyn. Ther. 2010, 7, 61-75.
24. Schweitzer, V. G.; Somers, M. L. PHOTOFRIN-mediated photodynamic therapy for treatment of early stage (Tis-T2N0M0) SqCCa of oral cavity and oropharynx. Lasers Surg. Med. 2010, 42, 1-8.
25. Fien, S. M.; Oseroff, A. R. Photodynamic therapy for non-melanoma skin cancer. J. Natl. Compr. Canc. Netw. 2007, 5, 531-540.
26. Kochneva, E. V.; Filonenko, E. V.; Vakulovskaya, E. G.; Scherbakova, E. G.; Seliverstov, O. V.; Markichev, N. A.; Reshetnickov, A. V. Photosensitizer Radachlorin(R): Skin cancer PDT phase II clinical trials. Photodiagnosis Photodyn. Ther. 2010, 7, 258-267.
27. Moore, C. M.; Pendse, D.; Emberton, M. Photodynamic therapy for prostate cancer-A review of current status and future promise. Nat. Clin. Pract. Urol. 2009, 6, 18-30.
28. Trachtenberg, J.; Weersink, R. A.; Davidson, S. R. H.; Haider, M. A.; Bogaards, A.; Gertner, M. R.; Evans, A.; Scherz, A.; Savard, J.; Chin, J. L.; et al. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int. 2008, 102, 556-562.
29. Selbo, P. K.; Weyergang, A.; Bonsted, A.; Bown, S. G.; Berg, K. Photochemical internalization of therapeutic macromolecular agents: A novel strategy to kill multidrug-resistant cancer cells. J. Pharmacol. Exp. Ther. 2006, 319, 604-612.
30. Josefsen, L. B.; Boyle, R. W. Photodynamic therapy: Novel third-generation photosensitizers one step closer? Br. J. Pharmacol. 2008, 154, 1-3.
31. Maisch, T. Anti-microbial photodynamic therapy: Useful in the future? Lasers Med. Sci. 2007, 22, 83-91.
32. Wormald, R.; Evans, J.; Smeeth, L.; Henshaw, K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2007, CD002030.
33. Tandon, Y. K.; Yang, M. F.; Baron, E. D. Role of photodynamic therapy in psoriasis: A brief review. Photodermatol. Photoimmunol. Photomed. 2008, 24, 222-230.
34. van der Snoek, E. M.; Robinson, D. J.; van Hellemond, J. J.; Neumann, H. A. A review of photodynamic therapy in cutaneous leishmaniasis. J. Eur. Acad. Dermatol. Venereol. 2008, 22, 918-922.
35. Wilson, B. C.; Patterson, M. S. The physics, biophysics and technology of photodynamic therapy. Phys. Med. Biol. 2008, 53, R61-R109.
36. Choudhary, S.; Nouri, K.; Elsaie, M. L. Photodynamic therapy in dermatology: A review. Lasers Med. Sci. 2009, 24, 971-980.
37. Dai, T.; Huang, Y. Y.; Hamblin, M. R. Photodynamic therapy for localized infections-State of the art. Photodiagnosis Photodyn. Ther. 2009, 6, 170-188.
38. Huang, Z.; Xu, H.; Meyers, A. D.; Musani, A. I.; Wang, L.; Tagg, R.; Barqawi, A. B.; Chen, Y. K. Photodynamic therapy for treatment of solid tumors-Potential and technical challenges. Technol. Cancer Res. Treat. 2008, 7, 309-320.
39. Allison, R. R.; Mota, H. C.; Bagnato, V. S.; Sibata, C. H. Bio-nanotechnology and photodynamic therapy-State of the art review. Photodiagnosis Photodyn. Ther. 2008, 5, 19-28.
40. Mang, T. S. Lasers and light sources for PDT: Past, present and future. Photodiagnosis Photodyn. Ther. 2004, 1, 43-48.
41. Firczuk, M.; Nowis, D.; Goła{ogonek}b, J. PDT-induced inflammatory and host responses. Photochem. Photobiol. Sci. 2011, 10, 653-663.
42. Freitas, I.; Baronzio, G. F. Tumor hypoxia, reoxygenation and oxygenation strategies: Possible role in photodynamic therapy. J. Photochem. Photobiol. B Biol. 1991, 11, 3-30.
43. Ferrari, M. Frontiers in cancer nanomedicine: Directing mass transport through biological barriers. Trends Biotechnol. 2010, 28, 181-188.
44. Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Mechanisms in photodynamic therapy: Part three-Photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn. Ther. 2005, 2, 91-106.
45. Sternberg, E. D.; Dolphin, D.; Brückner, C. Porphyrin-based photosensitizers for use in photodynamic therapy. Tetrahedron 1998, 54, 4151-4202.
46. Konan, Y. N.; Gurny, R.; Allemann, E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B 2002, 66, 89-106.
47. Sharman, W. M.; van Lier, J. E.; Allen, C. M. Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev. 2004, 56, 53-76.
48. Bechet, D.; Couleaud, P.; Frochot, C.; Viriot, M. L.; Guillemin, F.; Barberi-Heyob, M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008, 26, 612-621.
49. Bugaj, A. M. Targeted photodynamic therapy-A promising strategy of tumor treatment. Photochem. Photobiol. Sci. 2011, 10, 1097-1109.
50. Macdonald, I. J.; Dougherty, T. J. Basic principles of photodynamic therapy. J. Porphyr. Phthalocyanines 2001, 05, 105-129.
51. Hamblin, M. R.; Mróz, P.; Mroz, P. Advances in Photodynamic Therapy: Basic, Translational and Clinical; Artech House: Norwood, MA, USA, 2008.
52. Winterbourn, C. C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008, 4, 278-286.
53. Redmond, R. W.; Kochevar, I. E. Spatially resolved cellular responses to singlet oxygen. Photochem. Photobiol. 2006, 82, 1178-1186.
54. Robertson, C. A.; Evans, D. H.; Abrahamse, H. Photodynamic therapy (PDT): A short review on cellular mechanisms and cancer research applications for PDT. J. Photochem. Photobiol. B Biol. 2009, 96, 1-8.
55. Oleinick, N. L.; Morris, R. L.; Belichenko, I. The role of apoptosis in response to photodynamic therapy: What, where, why, and how. Photochem. Photobiol. Sci. 2002, 1, 1-21.
56. Boyle, R. W.; Dolphin, D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 1996, 64, 469-485.
57. Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Mechanisms in photodynamic therapy: Part one-Photosensitizers, photochemistry and cellular localization. Photodiagnosis Photodyn. Ther. 2004, 1, 279-293.
58. Mojzisova, H.; Bonneau, S.; Brault, D. Structural and physico-chemical determinants of the interactions of macrocyclic photosensitizers with cells. Eur. Biophys. J. 2007, 36, 943-953.
59. Almeida, R. D.; Manadas, B. J.; Carvalho, A. P.; Duarte, C. B. Intracellular signaling mechanisms in photodynamic therapy. Biochim. Biophys. Acta 2004, 1704, 59-86.
60. Tsaytler, P. A.; C O'Flaherty, M.; Sakharov, D. V.; Krijgsveld, J.; Egmond, M. R. Immediate protein targets of photodynamic treatment in carcinoma cells. J. Proteome Res. 2008, 7, 3868-3878.
61. Baglo, Y.; Sousa, M. M. L.; Slupphaug, G.; Hagen, L.; Håvåg, S.; Helander, L.; Zub, K. A.; Krokan, H. E.; Gederaas, O. A. Photodynamic therapy with hexyl aminolevulinate induces carbonylation, posttranslational modifications and changed expression of proteins in cell survival and cell death pathways. Photochem. Photobiol. Sci. 2011, 10, 1137-1145.
62. Moor, A. C. Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B Biol. 2000, 57, 1-13.
63. Castano, A. P.; Demidova, T. N.; Hamblin, M. R. Mechanisms in photodynamic therapy: Part two-Cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn. Ther. 2005, 2, 1-23.
64. Buytaert, E.; Dewaele, M.; Agostinis, P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim. Biophys. Acta 2007, 1776, 86-107.
65. Pazos, M. d. C.; Nader, H. B. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz. J. Med. Biol. Res. 2007, 40, 1025-1035.
66. Castano, A. P.; Mroz, P.; Hamblin, M. R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6, 535-545.
67. van Duijnhoven, F. H.; Aalbers, R. I. J. M.; Rovers, J. P.; Terpstra, O. T.; Kuppen, P. J. K. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003, 207, 105-113.
68. Korbelik, M. Cancer vaccines generated by photodynamic therapy. Photochem. Photobiol. Sci. 2011, 10, 664-669.
69. Wilson, B. C.; Patterson, M. S.; Lilge, L. Implicit and explicit dosimetry in photodynamic therapy: A New paradigm. Lasers Med. Sci. 1997, 12, 182-199.
70. Caldwell, J.; Gardner, I.; Swales, N. An introduction to drug disposition: The basic principles of absorption, distribution, metabolism, and excretion. Toxicol. Pathol. 1995, 23, 102-114.
71. Ochsner, M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J. Photochem. Photobiol. B 1997, 39, 1-18.
72. Henderson, B. W.; Gollnick, S. O.; Snyder, J. W.; Busch, T. M.; Kousis, P. C.; Cheney, R. T.; Morgan, J. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004, 64, 2120-2126.
73. Bachor, R.; Hautmann, R.; Hasan, T. Comparison of two routes of photosensitizer administration for photodynamic therapy of bladder cancer. Urol. Res. 1994, 22, 21-23.
74. Kwitniewski, M.; Juzeniene, A.; Glosnicka, R.; Moan, J. Immunotherapy: A way to improve the therapeutic outcome of photodynamic therapy? Photochem. Photobiol. Sci. 2008, 7, 1011-1017.
75. Bown, S. G.; Rogowska, A. Z.; Whitelaw, D. E.; Lees, W. R.; Lovat, L. B.; Ripley, P.; Jones, L.; Wyld, P.; Gillams, A.; Hatfield, A. W. Photodynamic therapy for cancer of the pancreas. Gut 2002, 50, 549-557.
76. Nelson, A. L.; Reichert, J. M. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 2009, 27, 331-337.
77. Deyev, S. M.; Lebedenko, E. N. Multivalency: The hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 2008, 30, 904-918.
78. Salfeld, J. G. Isotype selection in antibody engineering. Nat. Biotechnol. 2007, 25, 1369-1372.
79. Roopenian, D. C.; Akilesh, S. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715-725.
80. Golay, J.; Introna, M. Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. Arch. Biochem. Biophys. 2012, 526, 146-153.
81. Arnold, J. N.; Wormald, M. R.; Sim, R. B.; Rudd, P. M.; Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25, 21-50.
82. Rothlisberger, D.; Honegger, A.; Pluckthun, A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 2005, 347, 773-789.
83. Quintero-Hernández, V.; Del Pozo-Yauner, L.; Pedraza-Escalona, M.; Juárez-González, V. R.; Alcántara-Recillas, I.; Possani, L. D.; Becerril, B. Evaluation of three different formats of a neutralizing single chain human antibody against toxin Cn2: Neutralization capacity versus thermodynamic stability. Immunol. Lett. 2012, 143, 152-160.
84. Carmichael, J. A.; Power, B. E.; Garrett, T. P. J.; Yazaki, P. J.; Shively, J. E.; Raubischek, A. A.; Wu, A. M.; Hudson, P. J. The crystal structure of an anti-CEA scFv diabody assembled from T84. 66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Mol. Biol. 2003, 326, 341-351.
85. Kipriyanov, S. M.; Moldenhauer, G.; Braunagel, M.; Reusch, U.; Cochlovius, B.; Le Gall, F.; Kouprianova, O. A.; Von der Lieth, C. W.; Little, M. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J. Mol. Biol. 2003, 330, 99-111.
86. Cuesta, A. M.; Sainz-Pastor, N.; Bonet, J.; Oliva, B.; Alvarez-Vallina, L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol. 2010, 28, 355-362.
87. Todorovska, A.; Roovers, R. C.; Dolezal, O.; Kortt, A. A.; Hoogenboom, H. R.; Hudson, P. J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods 2001, 248, 47-66.
88. Kenanova, V.; Wu, A. M. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv. 2006, 3, 53-70.
89. Yuan, F.; Dellian, M.; Fukumura, D.; Leunig, M.; Berk, D. A.; Torchilin, V. P.; Jain, R. K. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res. 1995, 55, 3752-3756.
90. Batra, S. K.; Jain, M.; Wittel, U. A.; Chauhan, S. C.; Colcher, D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 2002, 13, 603-608.
91. Rudnick, S. I.; Adams, G. P. Affinity and avidity in antibody-based tumor targeting. Cancer Biother. Radiopharm. 2009, 24, 155-161.
92. Dahle, J.; Bagdonas, S.; Kaalhus, O.; Olsen, G.; Steen, H. B.; Moan, J. The bystander effect in photodynamic inactivation of cells. Biochim. Biophys. Acta 2000, 1475, 273-280.
93. Rubio, N.; Fleury, S. P.; Redmond, R. W. Spatial and temporal dynamics of in vitro photodynamic cell killing: Extracellular hydrogen peroxide mediates neighbouring cell death. Photochem. Photobiol. Sci. 2009, 8, 457-464.
94. Birchler, M.; Viti, F.; Zardi, L.; Spiess, B.; Neri, D. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol. 1999, 17, 984-988.
95. Conlon, K. A.; Berrios, M. Light-induced proteolysis of myosin heavy chain by Rose Bengalconjugated antibody complexes. J. Photochem. Photobiol. B 2001, 65, 22-28.
96. Conlon, K. A.; Rosenquist, T.; Berrios, M. Site-directed photochemical disruption of the actin cytoskeleton by actin-binding Rose Bengal-conjugates. J. Photochem. Photobiol. B 2002, 68, 140-146.
97. Hermanson, G. T. Bioconjugate Techniques; Academic Press: London, UK, 2008.
98. Bullous, A. J.; Alonso, C. M. A.; Boyle, R. W. Photosensitiser-antibody conjugates for photodynamic therapy. Photochem. Photobiol. Sci. 2011, 10, 721-750.
99. Giuntini, F.; Alonso, C. M. A.; Boyle, R. W. Synthetic approaches for the conjugation of porphyrins and related macrocycles to peptides and proteins. Photochem. Photobiol. Sci. 2011, 10, 759-791.
100. Mew, D.; Lum, V.; Wat, C. K.; Towers, G. H.; Sun, C. H.; Walter, R. J.; Wright, W.; Berns, M. W.; Levy, J. G. Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. Cancer Res. 1985, 45, 4380-4386.
101. Mew, D.; Wat, C. K.; Towers, G. H.; Levy, J. G. Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J. Immunol. 1983, 130, 1473-1477.
102. Steele, J. K.; Liu, D.; Stammers, A. T.; Whitney, S.; Levy, J. G. Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells. Cancer Immunol. Immunother. 1988, 26, 125-131.
103. Carcenac, M.; Dorvillius, M.; Garambois, V.; Glaussel, F.; Larroque, C.; Langlois, R.; Hynes, N. E.; van Lier, J. E.; Pèlegrin, A. Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates. Br. J. Cancer 2001, 85, 1787-1793.
104. Carcenac, M.; Larroque, C.; Langlois, R.; van Lier, J. E.; Artus, J. C.; Pèlegrin, A. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibodyphthalocyanine conjugates. Photochem. Photobiol. 1999, 70, 930-936.
105. Savellano, M. D.; Hasan, T. Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem. Photobiol. 2003, 77, 431-439.
106. Savellano, M. D.; Pogue, B. W.; Hoopes, P. J.; Vitetta, E. S.; Paulsen, K. D. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates. Cancer Res. 2005, 65, 6371-6379.
107. Bhatti, M.; Yahioglu, G.; Milgrom, L. R.; Garcia-Maya, M.; Chester, K. A.; Deonarain, M. P. Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. Int. J. Cancer 2008, 122, 1155-1163.
108. Soukos, N. S.; Hamblin, M. R.; Keel, S.; Fabian, R. L.; Deutsch, T. F.; Hasan, T. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res. 2001, 61, 4490-4496.
109. Fabbrini, M.; Trachsel, E.; Soldani, P.; Bindi, S.; Alessi, P.; Bracci, L.; Kosmehl, H.; Zardi, L.; Neri, D.; Neri, P. Selective occlusion of tumor blood vessels by targeted delivery of an antibodyphotosensitizer conjugate. Int. J. Cancer 2006, 118, 1805-1813.
110. Palumbo, A.; Hauler, F.; Dziunycz, P.; Schwager, K.; Soltermann, A.; Pretto, F.; Alonso, C.; Hofbauer, G. F.; Boyle, R. W.; Neri, D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br. J. Cancer 2011, 104, 1106-1115.
111. Vrouenraets, M. B.; Visser, G. W. M.; Stigter, M.; Oppelaar, H.; Snow, G. B.; van Dongen, G. A. M. S. Comparison of aluminium (III) phthalocyanine tetrasulfonate-and metatetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro. Int. J. Cancer 2002, 98, 793-798.
112. Vrouenraets, M. B.; Visser, G. W.; Stewart, F. A.; Stigter, M.; Oppelaar, H.; Postmus, P. E.; Snow, G. B.; van Dongen, G. A. Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res. 1999, 59, 1505-1513.
113. Vrouenraets, M. B.; Visser, G. W.; Loup, C.; Meunier, B.; Stigter, M.; Oppelaar, H.; Stewart, F. A.; Snow, G. B.; van Dongen, G. A. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy. Int. J. Cancer 2000, 88, 108-114.
114. Vrouenraets, M. B.; Visser, G. W.; Stigter, M.; Oppelaar, H.; Snow, G. B.; van Dongen, G. A. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res. 2001, 61, 1970-1975.
115. Sutton, J. M.; Clarke, O. J.; Fernandez, N.; Boyle, R. W. Porphyrin, chlorin, and bacteriochlorin isothiocyanates: Useful reagents for the synthesis of photoactive bioconjugates. Bioconjug. Chem. 2002, 13, 249-263.
116. Hudson, R.; Carcenac, M.; Smith, K.; Madden, L.; Clarke, O. J.; Pèlegrin, A.; Greenman, J.; Boyle, R. W. The development and characterisation of porphyrin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy. Br. J. Cancer 2005, 92, 1442-1449.
117. Staneloudi, C.; Smith, K. A.; Hudson, R.; Malatesti, N.; Savoie, H.; Boyle, R. W.; Greenman, J. Development and characterization of novel photosensitizer: scFv conjugates for use in photodynamic therapy of cancer. Immunology 2007, 120, 512-517.
118. Smith, K.; Malatesti, N.; Cauchon, N.; Hunting, D.; Lecomte, R.; van Lier, J. E.; Greenman, J.; Boyle, R. W. Mono-and tri-cationic porphyrin-monoclonal antibody conjugates: Photodynamic activity and mechanism of action. Immunology 2011, 132, 256-265.
119. Malatesti, N.; Smith, K.; Savoie, H.; Greenman, J.; Boyle, R. W. Synthesis and in vitro investigation of cationic 5, 15-diphenyl porphyrin-monoclonal antibody conjugates as targeted photodynamic sensitisers. Int. J. Oncol. 2006, 28, 1561-1569.
120. Alonso, C. M. A.; Palumbo, A.; Bullous, A. J.; Pretto, F.; Neri, D.; Boyle, R. W. Site-specific and stoichiometric conjugation of cationic porphyrins to antiangiogenic monoclonal antibodies. Bioconjug. Chem. 2010, 21, 302-313.
121. Hamblin, M. R.; Del Governatore, M.; Rizvi, I.; Hasan, T. Biodistribution of charged 17. 1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. Br. J. Cancer 2000, 83, 1544-1551.
122. Duska, L. R.; Hamblin, M. R.; Bamberg, M. P.; Hasan, T. Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer. Br. J. Cancer 1997, 75, 837-844.
123. Duska, L. R.; Hamblin, M. R.; Miller, J. L.; Hasan, T. Combination photoimmunotherapy and cisplatin: effects on human ovarian cancer ex vivo. J. Natl. Cancer Inst. 1999, 91, 1557-1563.
124. Hamblin, M. R.; Miller, J. L.; Hasan, T. Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res. 1996, 56, 5205-5210.
125. Del Governatore, M.; Hamblin, M. R.; Shea, C. R.; Rizvi, I.; Molpus, K. G.; Tanabe, K. K.; Hasan, T. Experimental photoimmunotherapy of hepatic metastases of colorectal cancer with a 17. 1A chlorin(e6) immunoconjugate. Cancer Res. 2000, 60, 4200-4205.
126. Molpus, K. L.; Hamblin, M. R.; Rizvi, I.; Hasan, T. Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol. Oncol. 2000, 76, 397-404.
127. Del Governatore, M.; Hamblin, M. R.; Piccinini, E. E.; Ugolini, G.; Hasan, T. Targeted photodestruction of human colon cancer cells using charged 17. 1A chlorin e6 immunoconjugates. Br. J. Cancer 2000, 82, 56-64.
128. Jiang, F. N.; Jiang, S.; Liu, D.; Richter, A.; Levy, J. G. Development of technology for linking photosensitizers to a model monoclonal antibody. J. Immunol. Methods 1990, 134, 139-149.
129. Jiang, F. N.; Allison, B.; Liu, D.; Levy, J. G. Enhanced photodynamic killing of target cells by either monoclonal antibody or low density lipoprotein mediated delivery systems. J. Control Release 1992, 19, 41-58.
130. Jiang, F. N.; Liu, D. J.; Neyndorff, H.; Chester, M.; Jiang, S. Y.; Levy, J. G. Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J. Natl. Cancer Inst. 1991, 83, 1218-1225.
131. Berthiaume, F.; Reiken, S. R.; Toner, M.; Tompkins, R. G.; Yarmush, M. L. Antibody-targeted photolysis of bacteria in vivo. Biotechnology (N. Y.) 1994, 12, 703-706.
132. Strong, L. H.; Berthiaume, F.; Yarmush, M. L. Control of fibroblast populated collagen lattice contraction by antibody targeted photolysis of fibroblasts. Lasers Surg. Med. 1997, 21, 235-247.
133. Thorpe, W. P.; Toner, M.; Ezzell, R. M.; Tompkins, R. G.; Yarmush, M. L. Dynamics of photoinduced cell plasma membrane injury. Biophys. J. 1995, 68, 2198-2206.
134. Lu, X. M.; Fischman, A. J.; Stevens, E.; Lee, T. T.; Strong, L.; Tompkins, R. G.; Yarmush, M. L. Sn-chlorin e6 antibacterial immunoconjugates. An in vitro and in vivo analysis. J. Immunol. Methods 1992, 156, 85-99.
135. Hasan, T.; Lin, A.; Yarmush, D.; Oseroff, A.; Yarmush, M. Monoclonal antibody-chromophore conjugates as selective phototoxins. J. Control Release 1989, 10, 107-117.
136. Goff, B. A.; Hermanto, U.; Rumbaugh, J.; Blake, J.; Bamberg, M.; Hasan, T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br. J. Cancer 1994, 70, 474-480.
137. Goff, B. A.; Bamberg, M.; Hasan, T. Photoimmunotherapy of human ovarian carcinoma cells ex vivo. Cancer Res. 1991, 51, 4762-4767.
138. Goff, B. A.; Blake, J.; Bamberg, M. P.; Hasan, T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br. J. Cancer 1996, 74, 1194-1198.
139. Savellano, M. D.; Owusu-Brackett, N.; Son, J.; Ganga, T.; Leung, N. L.; Savellano, D. H. Photodynamic Tumor Eradication With a Novel Targetable Photosensitizer: Strong Vascular Effects and Dependence on Treatment Repetition Versus Potentiation. Photochem. Photobiol. 2012, doi: 10. 1111/php. 12018.
140. Dumontet, C.; Jordan, M. A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9, 790-803.
141. Pèlegrin, A.; Folli, S.; Buchegger, F.; Mach, J. P.; Wagnières, G.; van den Bergh, H. Antibodyfluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer 1991, 67, 2529-2537.
142. Kuimova, M. K.; Bhatti, M.; Deonarain, M.; Yahioglu, G.; Levitt, J. A.; Stamati, I.; Suhling, K.; Phillips, D. Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosensitizer conjugates suitable for photodynamic therapy. Photochem. Photobiol. Sci. 2007, 6, 933-939.
143. Bhatti, M.; MacRobert, A.; Henderson, B.; Shepherd, P.; Cridland, J.; Wilson, M. Antibodytargeted lethal photosensitization of Porphyromonas gingivalis. Antimicrob. Agents Chemother. 2000, 44, 2615-2618.
144. Stuchinskaya, T.; Moreno, M.; Cook, M. J.; Edwards, D. R.; Russell, D. A. Targeted photodynamic therapy of breast cancer cells using antibody-phthalocyanine-gold nanoparticle conjugates. Photochem. Photobiol. Sci. 2011, 10, 822-831.
145. Bulina, M. E.; Chudakov, D. M.; Britanova, O. V.; Yanushevich, Y. G.; Staroverov, D. B.; Chepurnykh, T. V.; Merzlyak, E. M.; Shkrob, M. A.; Lukyanov, S.; Lukyanov, K. A. A genetically encoded photosensitizer. Nat. Biotechnol. 2005, 24, 95-99.
146. Vegh, R. B.; Solntsev, K. M.; Kuimova, M. K.; Cho, S.; Liang, Y.; Loo, B. L. W.; Tolbert, L. M.; Bommarius, A. S. Reactive oxygen species in photochemistry of the red fluorescent protein "Killer Red". Chem. Commun. (Camb.) 2011, 47, 4887-4889.
147. Serebrovskaya, E.; Stremovsky, O.; Chudakov, D.; Lukyanov, K.; Deyev, S. Genetically encoded immunophotosensitizer. Russ. J. Bioorg. Chem. 2011, 37, 123-129.
148. Serebrovskaya, E. O.; Edelweiss, E. F.; Stremovskiy, O. A.; Lukyanov, K. A.; Chudakov, D. M.; Deyev, S. M. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein. Proc. Natl. Acad. Sci. USA 2009, 106, 9221-9225.
149. Oseroff, A. R.; Ohuoha, D.; Hasan, T.; Bommer, J. C.; Yarmush, M. L. Antibody-targeted photolysis: Selective photodestruction of human T-cell leukemia cells using monoclonal antibody-chlorin e6 conjugates. Proc. Natl. Acad. Sci. USA 1986, 83, 8744-8748.
150. Yarmush, M. L.; Thorpe, W. P.; Strong, L.; Rakestraw, S. L.; Toner, M.; Tompkins, R. G. Antibody Targeted Photolysis. Crit. Rev. Ther. Drug Carrier Syst. 1993, 10, 197-252.
151. Savellano, M. D.; Hasan, T. Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin. Cancer Res. 2005, 11, 1658-1668.
152. Kaspar, M.; Zardi, L.; Neri, D. Fibronectin as target for tumor therapy. Int. J. Cancer 2006, 118, 1331-1339.
153. Pini, A.; Viti, F.; Santucci, A.; Carnemolla, B.; Zardi, L.; Neri, P.; Neri, D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 1998, 273, 21769-21776.
154. Stamati, I.; Kuimova, M. K.; Lion, M.; Yahioglu, G.; Phillips, D.; Deonarain, M. P. Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro. Photochem. Photobiol. Sci. 2010, 9, 1033-1041.
155. Folli, S.; Wagnières, G.; Pèlegrin, A.; Calmes, J. M.; Braichotte, D.; Buchegger, F.; Chalandon, Y.; Hardman, N.; Heusser, C.; Givel, J. C. Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. Proc. Natl. Acad. Sci. USA 1992, 89, 7973-7977.
156. Collins, H. A.; Khurana, M.; Moriyama, E. H.; Mariampillai, A.; Dahlstedt, E.; Balaz, M.; Kuimova, M. K.; Drobizhev, M.; Yang, V. X. D.; Phillips, D.; et al. Blood-vessel closure using photosensitizers engineered for two-photon excitation. Nat. Photonics. 2008, 2, 420-424.
157. Khurana, M.; Collins, H. A.; Karotki, A.; Anderson, H. L.; Cramb, D. T.; Wilson, B. C. Quantitative in vitro demonstration of two-photon photodynamic therapy using photofrin and visudyne. Photochem. Photobiol. 2007, 83, 1441-1448.
158. Pawlicki, M.; Collins, H. A.; Denning, R. G.; Anderson, H. L. Two-photon absorption and the design of two-photon dyes. Angew. Chem. Int. Ed. Engl. 2009, 48, 3244-3266.
159. Kuroki, M.; Hachimine, K.; Abe, H.; Shibaguchi, H.; Kuroki, M.; Maekawa, S.-I.; Yanagisawa, J.; Kinugasa, T.; Tanaka, T.; Yamashita, Y. Sonodynamic therapy of cancer using novel sonosensitizers. Anticancer Res. 2007, 27, 3673-3677.
160. Ma, X.; Pan, H.; Yi, J. Combination sonodynamic therapy with immunoadjuvant may be a promising new modality for cancer treatment. Med. Hypotheses 2009, 72, 418-420.
161. Yamaguchi, S.; Kobayashi, H.; Narita, T.; Kanehira, K.; Sonezaki, S.; Kudo, N.; Kubota, Y.; Terasaka, S.; Houkin, K. Sonodynamic therapy using water-dispersed TiO2-polyethylene glycol compound on glioma cells: Comparison of cytotoxic mechanism with photodynamic therapy. Ultrason. Sonochem. 2011, 18, 1197-1204.
162. Huang, X.; Jain, P. K.; El-Sayed, I. H.; El-Sayed, M. A. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med. Sci. 2008, 23, 217-228.
163. Huang, X.; Qian, W.; El-Sayed, I. H.; El-Sayed, M. A. The potential use of the enhanced nonlinear properties of gold nanospheres in photothermal cancer therapy. Lasers Surg. Med. 2007, 39, 747-753.
164. El-Sayed, I. H.; Huang, X.; El-Sayed, M. A. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006, 239, 129-135.
165. Liu, Y.; Chen, W.; Wang, S.; Joly, A. G. Investigation of water-soluble X-ray luminescence nanoparticles for photodynamic activation. Appl. Phys. Lett. 2008, 92, 043901-043901-043903.
166. Samia, A. C. S.; Dayal, S.; Burda, C. Quantum dot-based energy transfer: perspectives and potential for applications in photodynamic therapy. Photochem. Photobiol. 2006, 82, 617-625.
167. Juzenas, P.; Chen, W.; Sun, Y.-P.; Coelho, M. A. N.; Generalov, R.; Generalova, N.; Christensen, I. L. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv. Drug Deliv. Rev. 2008, 60, 1600-1614.
168. Chen, W.; Zhang, J. Using nanoparticles to enable simultaneous radiation and photodynamic therapies for cancer treatment. J. Nanosci. Nanotechnol. 2006, 6, 1159-1166.
169. Vaidya, A.; Sun, Y.; Feng, Y.; Emerson, L.; Jeong, E.-K.; Lu, Z.-R. Contrast-enhanced MRIguided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate. Pharm. Res. 2008, 25, 2002-2011.
170. Huang, P.; Li, Z.; Lin, J.; Yang, D.; Gao, G.; Xu, C.; Bao, L.; Zhang, C.; Wang, K.; Song, H.; Hu, H.; Cui, D. Photosensitizer-conjugated magnetic nanoparticles for in vivo simultaneous magnetofluorescent imaging and targeting therapy. Biomaterials 2011, 32, 3447-3458.
171. Detty, M. R. Direct 1270 nm irradiation as an alternative to photosensitized generation of singlet oxygen to induce cell death. Photochem. Photobiol. 2012, 88, 2-4.
172. Laptev, R.; Nisnevitch, M.; Siboni, G.; Malik, Z.; Firer, M. A. Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells. Br. J. Cancer 2006, 95, 189-196.
173. Embleton, M. L.; Nair, S. P.; Cookson, B. D.; Wilson, M. Antibody-directed photodynamic therapy of methicillin resistant Staphylococcus aureus. Microb. Drug Resist. 2004, 10, 92-97.
174. Berki, T.; Németh, P. Novel method for in vitro depletion of T cells by monoclonal antibodytargeted photosensitization. J. Immunol. Methods 1998, 211, 139-146.